CClinicalTrials.gg
CompletedNCT01116934Updated Mar 24, 2016Results posted

Cytokines in Papillon-Lefèvre Syndrome

An observational study in Papillon-Lefevre Disease, sponsored by Goethe University. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2016-03-24.

Sponsored by Goethe University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
17
Sex
All
01

Study summary

Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by "loss of function" mutations in the cathepsin C gene. The hypothesis behind this study is that PLS patients' PMNs produce more proinflammatory cytokines to compensate for their reduced capacity to neutralize leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study was to evaluate the cytokine profile in PLS patients' blood cultures.

Read the detailed description

MATERIAL AND METHODS Materials Lipopolysaccharide (LPS; Escherichia coli, serotype R515) was purchased from Alexis (Lausen, Switzerland) and adenosine triphosphate (ATP) from Sigma (Deisenhofen, Germany). Tumor necrosis factor α (TNF-α) was kindly provided by the Knoll AG (Ludwigshafen, Germany). IL-1β was from Invitrogen/Biosource (Karlsruhe, Germany).

Patients and healthy donors Five patients with established diagnose of PLS are under periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum) of the Johann Wolfgang Goethe-University Frankfurt am Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and they are under regular and frequent supportive therapy. The Department of Periodontology has contact to additional 5 PLS patients that are edentulous or under periodontal therapy elsewhere. All patients underwent complete oral examinations as well as inspection of the skin of the palms and soles. Each adult patient or parents received clinical and genetic counselling, and signed a consent form, approved by the ethic committees of the Universities of Dresden and Frankfurt/Main. Clinical data and mutations of all patients have been reported before. All these patients were invited to take part in this study. Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen. The study complied with the rules of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies of the Medical Faculty of the Johann Wolfgang Goethe-University Frankfurt/Main (Application# 31/05). All participating individuals were informed on risks and benefit as well as the procedures of the study and gave written informed consent.

Whole blood culture Heparinized blood was mixed with an equal volume of culture medium (RPMI 1640 supplemented with 25 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), 100 U/ml penicillin, 100 µg/ml streptomycin) and 1 ml aliquots were transferred into loosely sealed round-bottom polypropylene tubes (Greiner, Germany). Whole blood cultures were kept at 37 oC and 5 % CO2 for the indicated time periods. Thereafter, cell-free plasma/RPMI samples were obtained by centrifugation and stored at -70oC until assessment of cytokine concentrations by enzyme linked immunosorbent essay (ELISA). Experiments were started within 60 min of blood withdrawal. Thus, the whole blood cultures consisted of the whole range of white blood cells as well as erythrocytes. Except for determination of IL-1β release, cultures were either kept as unstimulated control or stimulated with LPS (10 or 100 ng/ml), or with the combination of IL-1β plus TNF-α (50 ng/ml each) for 24h. For determination of IL-1β release, cells were kept as unstimulated control or were stimulated with Toll-like receptor 4 ligand LPS (100 ng/ml) for altogether 5h. For efficient release of IL-1β from activated cultures, LPS was combined with ATP (2 mM) which was added during the last 2h of the 5h stimulation period in order to achieve activation of the purinoreceptor P2X7.

Analysis of cytokine release by ELISA analysis Concentrations of IL-8, IL-6, interferon-inducible protein (IP)-10, interferon (IFN) gamma (Pharmingen/BD Biosciences), and IL-1β, (R\&D Systems), in plasma/RPMI samples were determined by ELISA according to the manufacturers' instructions.

Statistics The individual patient or proband was defined as statistical unit. Data are shown as median with interquartile range and are presented as pg/ml (IL-1β, IL-6, IP-10) or as ng/ml (IL-8). Medians were compared between PLS patients and healthy volunteers using the non parametric Mann Whitney U test. Statistical analysis was performed using a computer program (Systat for Windows version 10.0, Systat Inc., Evanston, IL, USA).

02

Conditions studied

  • Papillon-Lefevre Disease

Keywords

  • blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma
03

In context

Lead sponsor

Goethe University is the lead sponsor of 97 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

5 patients with established diagnose of PLS are under periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum) of the JWG-University Frankfurt am Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and they are under regular and frequent supportive therapy. The Department of Periodontology has contact to additional 5 PLS patients that are edentulous or under periodontal therapy elsewhere.

Inclusion criteria

  • Diagnose of PLS

Exclusion criteria

Exclusion Criteria:

  • No written informed consent
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
17 participants (actual)

Groups and cohorts

  • PLS patients

    Eight PLS patients (one female) from 6 families.

  • Healthy controls

    Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.

06

What researchers measure

Primary outcomes

  1. Serum Concentrations of Interleukin (IL)-1 Beta

    Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions

    Time frame: 2006

07

Results

Posted Mar 24, 2016

Participant flow

Participant flow — Overall Study
MilestonePapillon-Lefèvre Syndrome (PLS) PatientsHealthy Controls
Started89
Completed89
Not completed00

Outcome measures

PrimarySerum Concentrations of Interleukin (IL)-1 Beta

Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions

Time frame:
2006
Reported as:
Median · pg/ml
Serum Concentrations of Interleukin (IL)-1 Beta
pg/mlPapillon-Lefèvre Syndrome (PLS) PatientsHealthy Controls
interleukin-1 beta1100.00 (896.21 to 2572.10)896.21 (771.15 to 2014.00)
interleukin-665559 (40365 to 108260)45734 (34056 to 66365)
interferon-inducible protein-1012902.5 (8105.5 to 15735.5)11563 (9164 to 19758)
interferon gamma3704.5 (2629.5 to 4372.8)3317.4 (2538.5 to 5487.8)
interleukin-850520 (29280 to 79870)44390 (24680 to 46580)

Adverse events

Collected over Patients were asked to report AEs from blood sampling if they occured.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLS Patients—0/8 (0%)0/8 (0%)
Healthy Controls—0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PLS PatientsHealthy ControlsTotal
<=18 years505
Between 18 and 65 years3912
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)PLS PatientsHealthy ControlsTotal
Female101
Male7916
Region of Enrollment
Region of Enrollment(participants)PLS PatientsHealthy ControlsTotal
Germany8917
08

Study locations

1 site
  • Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum), JWG-University
    Frankfurt/Main, 60596, Germany
09

References and documents

Publications

  • Eickholz P, Kugel B, Pohl S, Naher H, Staehle HJ. Combined mechanical and antibiotic periodontal therapy in a case of Papillon-Lefevre syndrome. J Periodontol. 2001 Apr;72(4):542-9. doi: 10.1902/jop.2001.72.4.542. PubMed 11338309 ↗
  • Noack B, Gorgens H, Hoffmann T, Fanghanel J, Kocher T, Eickholz P, Schackert HK. Novel mutations in the cathepsin C gene in patients with pre-pubertal aggressive periodontitis and Papillon-Lefevre syndrome. J Dent Res. 2004 May;83(5):368-70. doi: 10.1177/154405910408300503. PubMed 15111626 ↗
  • Lux CJ, Kugel B, Komposch G, Pohl S, Eickholz P. Orthodontic treatment in a patient with Papillon-Lefevre syndrome. J Periodontol. 2005 Apr;76(4):642-50. doi: 10.1902/jop.2005.76.4.642. PubMed 15857107 ↗
  • Schacher B, Baron F, Ludwig B, Valesky E, Noack B, Eickholz P. Periodontal therapy in siblings with Papillon-Lefevre syndrome and tinea capitis: a report of two cases. J Clin Periodontol. 2006 Nov;33(11):829-36. doi: 10.1111/j.1600-051X.2006.00992.x. Epub 2006 Sep 13. PubMed 16970621 ↗
  • Noack B, Gorgens H, Schacher B, Puklo M, Eickholz P, Hoffmann T, Schackert HK. Functional Cathepsin C mutations cause different Papillon-Lefevre syndrome phenotypes. J Clin Periodontol. 2008 Apr;35(4):311-6. doi: 10.1111/j.1600-051X.2008.01201.x. Epub 2008 Feb 20. PubMed 18294227 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01116934
Lead sponsor
Goethe University
Responsible party
Peter Eickholz (Prof. Dr. med. dent., Goethe University) — Principal investigator
First posted
May 5, 2010
Start date
Jul 2006
Primary completion
Jan 2007
Completion
Dec 2009
Results posted
Mar 24, 2016
Last update
Mar 24, 2016

Study contacts

Peter Eickholz, Prof. Dr.
study chair · JWG-University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion